Dianthus Therapeutics (DNTH) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Dianthus Therapeutics (DNTH) over the past year, gaining 197.1% versus a gain of 144.6%. Over five years, TNGX leads with a +54.4% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $3.68 billion), about 1.3 times the size, while Tango Therapeutics is growing revenue faster (+48.3% vs -67.3%).
Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | TNGX |
|---|---|---|
| Share price | $84.88 | $21.83 |
| Market cap | $4.75B | $3.68B |
| 1-day change | -0.61% | -0.32% |
| YTD return | +105.97% | +144.47% |
| 1-year return | +144.61% | +197.12% |
| 5-year return | -21.17% | +54.38% |
| EPS (TTM) | $-4.24 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $62.38M |
| Revenue growth (YoY) | -67.35% | +48.29% |
| Net income (latest FY) | $-162.34M | $-101.59M |
| Operating margin | -8739.34% | -178.39% |
| Net margin | -7973.33% | -162.85% |
| 52-week high | $117.88 | $34.39 |
| 52-week low | $32.22 | $6.69 |
| Distance from 52-week high | -27.99% | -36.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.88% | +106.96% |
| Average volume | 825.33K | 2.60M |
| Shares outstanding | 55.93M | 168.61M |
| Employees | 92 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed DNTH by 52.5 percentage points over the past year.
- Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Tango Therapeutics grew revenue faster in its latest fiscal year (+48.29% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
DNTH vs TNGX FAQ
Which is bigger, Dianthus Therapeutics or Tango Therapeutics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $3.68B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, DNTH or TNGX?
TNGX returned +197.12% over the past 12 months, compared with +144.61% for DNTH (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.